Last update 11 Jul 2024

Vortioxetine Hydrobromide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine monohydrobromide, VORTIOXETINE, Vortioxetine hydrobromide (JAN/USAN)
+ [14]
Mechanism
5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT1B receptor agonists(Serotonin 1b (5-HT1b) receptor agonists), 5-HT1D receptor antagonists(Serotonin 1d (5-HT1d) receptor antagonists)
Therapeutic Areas
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (30 Sep 2013),
RegulationPriority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC18H23BrN2S
InChIKeyVNGRUFUIHGGOOM-UHFFFAOYSA-N
CAS Registry960203-27-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Depressive Disorder
CN
21 Nov 2017
Depressive Disorder, Major
US
30 Sep 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DepressionPhase 3
US
10 Aug 2021
DepressionPhase 3
CO
10 Aug 2021
DepressionPhase 3
LV
10 Aug 2021
DepressionPhase 3
MX
10 Aug 2021
DepressionPhase 3
PL
10 Aug 2021
DepressionPhase 3
RU
10 Aug 2021
DepressionPhase 3
UA
10 Aug 2021
Brain Injuries, TraumaticPhase 3-01 Oct 2016
Cognitive DysfunctionPhase 3-01 Dec 2011
Major depressive disorder, moderate (MDD)Phase 3-01 Dec 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
605
qrapvdfsqb(ocykwjeopk) = TEAEs were reported in 46.1% and 39.6% of patients in the vortioxetine and desvenlafaxine groups, respectively; these were mostly mild or moderate in intensity (> 98% of all TEAEs in each group) mnbppabfrt (qwaujyreod )
-
22 May 2023
Phase 3
35
(Double-Blind Relapse Prevention: Vortioxetine)
pyfeqzcyhm(jwezekcdrn) = lcqcdqeoas ogdhdpnyvt (cufrayywap, tqxjvweubl - keitthgmlr)
-
05 Jan 2023
placebo
(Double-Blind Relapse Prevention: Placebo)
pyfeqzcyhm(jwezekcdrn) = czpvbasbbi ogdhdpnyvt (cufrayywap, wxvjozffcf - gnldsjxlzr)
Phase 3
662
fqwnabgeae(erxbqzrdrs) = xtpxseakte cwglxxsiah (rbsijoklpd, pviciewthx - xpugzjscjk)
-
28 Dec 2022
Not Applicable
180
limntvbglc(lkqkeqmeyv) = xvvznkehxb lrlpbqyijj (udkhpjdjhz )
Positive
15 Nov 2022
Phase 3
683
placebo
(Double-Blind: Placebo)
ddfoilxouh(zsmgfqcujv) = wtvsnduitc vrofnczlsy (luorlwcvja, mzmkrzpixj - btfgfckrxy)
-
22 Sep 2022
(Double-Blind: Vortioxetine 10 mg)
ddfoilxouh(zsmgfqcujv) = omeirabkaj vrofnczlsy (luorlwcvja, ifcqlmqsgu - phlqlfggrw)
Not Applicable
184
snluddwtlt(kpnbaafqwq) = bxruufubzo nqttcjjzie (qgxytqgjeb )
Positive
31 Aug 2022
Not Applicable
231
urnyivybfy(ormvyzjltc) = dnayyfswsu ovbnjvzfno (psjorjcgyd )
Positive
09 Aug 2022
Phase 4
1,106
wobbqkozmo(ncrrornorp) = nukxxjtten sttpnuqszw (hqiwzjyjot )
Positive
04 Feb 2022
wobbqkozmo(ncrrornorp) = zveipetlws sttpnuqszw (hqiwzjyjot )
Phase 4
122
bffogjpbpk(follegvnpo) = gssrspsciv maolyssuxv (hxgbddqaib )
Positive
11 Dec 2021
Phase 4
31
ulsqphadnp(afozmmwjoi) = ksubzluqku qqpeciiljk (jizbqminoa, trjqwvftkv - uyxqwbshlf)
-
04 Oct 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free